RXRX PEER ANALYSIS

Recursion Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

RXRXRecursion Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

RXRXIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	RXRX	TLX	MSB	CSL	Ind. Median
P/E	—	—	—	29.44	17.91
P/B	1.96●	6.37	—	2.20	3.51
EV/EBITDA	—	120.14	—	10.21●	14.82
P/S	30.34	3.24	31.61	2.62●	10.89

Financial Health
Metric	RXRX	TLX	MSB	CSL	Ind. Median
Current Ratio	5.47●	1.43	—	2.57	5.90
Debt/Equity	7.1%●	112.3%	—	67.4%	10.9%
NetDebt/EBITDA	1.21●	13.13	—	2.22	1.15

Profitability
Metric	RXRX	TLX	MSB	CSL	Ind. Median
Net Margin	-844.5%	-0.9%	-115.3%	9.2%●	-125.7%
ROE	-57.2%	-1.8%	-11.3%	7.7%●	-47.5%
ROA	-42.3%	-0.7%	-8.6%	3.8%●	-35.8%
EBITDA Margin	-723.3%	3.0%	-76.6%	32.8%●	-105.8%

Growth + Dividend
Metric	RXRX	TLX	MSB	CSL	Ind. Median
Rev. Growth	11.0%	56.3%	410.4%●	4.8%	5.1%
NI Growth	—	—	—	-39.4%	12.1%
Div. Yield	—	—	0.0%	2.5%●	0.2%
Payout	—	—	0.0%	103.1%	0.0%

Valuation
Metric	RXRX	VRDN	ZYME	STOK	NTLA	URGN	Ind. Median
P/E	—	—	—	—	—	—	17.91
P/B	1.96	3.12	12.01	5.22	3.35	-15.36●	3.51
EV/EBITDA	—	—	—	—	—	—	14.82
P/S	30.34	27.96	24.18	64.28	31.48	13.58●	10.89

Financial Health
Metric	RXRX	VRDN	ZYME	STOK	NTLA	URGN	Ind. Median
Current Ratio	5.47	15.15●	10.82	8.99	6.10	4.69	5.90
Debt/Equity	7.1%	8.0%	10.4%	0.9%	13.0%	-158.6%●	10.9%
NetDebt/EBITDA	1.21	2.03	3.69	2.07	0.77	-0.48●	1.15

Profitability
Metric	RXRX	VRDN	ZYME	STOK	NTLA	URGN	Ind. Median
Net Margin	-844.5%	-508.5%	-126.3%	-529.2%	-597.0%	-94.8%●	-125.7%
ROE	-57.2%	-58.1%	-42.0%●	-45.6%	-56.3%	—	-47.5%
ROA	-42.3%	-49.7%	-22.7%●	-39.9%	-45.2%	-53.2%	-35.8%
EBITDA Margin	-723.3%	-492.7%	-116.1%	-511.5%	-581.9%	-82.4%●	-105.8%

Growth + Dividend
Metric	RXRX	VRDN	ZYME	STOK	NTLA	URGN	Ind. Median
Rev. Growth	11.0%	23,382.8%●	-13.0%	-83.2%	45.0%	52.9%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on RXRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.